Clinical Trial Update: Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ranibizumab intravitreal injections versus dexamethasone intravitreal implant in branch retinal vein occlusion evaluated efficacy and sa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Branch Retinal Vein Occlusion
• Macular Edema

Drugs mentioned

• Lucentis (ranibizumab)
• Ozurdex (dexamethasone intravitreal implant)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Visual Impairment, Macular Edema | Phase 3 | Status: COMPLETED | Results posted: 2014-07-16